acquired
Stage
About
Spark Therapeutics is a biotechnology company focused on developing and commercializing adeno-associated virus (AAV)-based gene therapies for inherited genetic diseases; it developed and brought to market Luxturna (voretigene neparvovec) for an inherited retinal dystrophy.
Explore Spark Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.